News
Zacks.com on MSN14h
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should KnowIn the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.
MarketBeat on MSN1d
Hims’ Weight Loss Expansion: Real Growth or Just Hype?Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...
Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...
The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.
Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part ...
LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...
In its first quarter 2025 investor letter, ClearBridge Small Cap Growth Strategy emphasized stocks such as Hims & Hers Health, Inc. (NYSE:HIMS). Hims & Hers Health, Inc. (NYSE:HIMS) offers a ...
Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.
The stock market has recently witnessed significant movements among key players in the technology and healthcare sectors.
StockStory.org on MSN2d
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To KnowWhat Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback